NewLink Genetics Corp. (NLNK)

4.67
NASDAQ : Health Technology
Prev Close 4.56
Day Low/High 4.46 / 4.80
52 Wk Low/High 3.75 / 19.30
Avg Volume 564.90K
Exchange NASDAQ
Shares Outstanding 37.16M
Market Cap 169.47M
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)
(Graphic: Business Wire)

(Graphic: Business Wire)

NewLink Genetics Corporation (NASDAQ:NLNK), reported that updated Phase 1 data evaluating indoximod plus front-line radiation and maintenance chemotherapy for the treatment of pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG)...

Yousef Zakharia, MD, Assistant Professor Of Medicine, Division Of Hematology, Oncology And Blood & Marrow Transplantation At The University Of Iowa And Holden Comprehensive Cancer Center Gives An Overview Of NewLink Genetics Clinical Trial Of Indoximod

Yousef Zakharia, MD, Assistant Professor Of Medicine, Division Of Hematology, Oncology And Blood & Marrow Transplantation At The University Of Iowa And Holden Comprehensive Cancer Center Gives An Overview Of NewLink Genetics Clinical Trial Of Indoximod

NewLink Genetics Corporation (NASDAQ:NLNK) today announced that data from two Phase 2 studies of indoximod, used in combination with other agents, were presented at the  2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

First Week Of June 15th Options Trading For NewLink Genetics (NLNK)

Investors in NewLink Genetics Corp saw new options become available this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NLNK options chain for the new June 15th contracts and identified one put and one call contract of particular interest.

NewLink Genetics Enters Oversold Territory (NLNK)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Buy NewLink Genetics Corp At $6, Earn 56.1% Annualized Using Options

Commit To Buy NewLink Genetics Corp At $6, Earn 56.1% Annualized Using Options

Investors eyeing a purchase of NewLink Genetics Corp stock, but tentative about paying the going market price of $8.10/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July put at the $6 strike, which has a bid at the time of this writing of $1.20.

NewLink Genetics Reports Fourth Quarter, Year-End 2017 Financial Results And Provides Update For Indoximod Programs

NewLink Genetics Reports Fourth Quarter, Year-End 2017 Financial Results And Provides Update For Indoximod Programs

Management to Host Conference Call Today at 4:30 p.m. ET

First Week of October 19th Options Trading For NewLink Genetics (NLNK)

First Week of October 19th Options Trading For NewLink Genetics (NLNK)

Investors in NewLink Genetics Corp saw new options become available this week, for the October 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Commit To Purchase NewLink Genetics Corp At $6, Earn 60.9% Annualized Using Options

Commit To Purchase NewLink Genetics Corp At $6, Earn 60.9% Annualized Using Options

Investors considering a purchase of NewLink Genetics Corp shares, but tentative about paying the going market price of $8.25/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April put at the $6 strike, which has a bid at the time of this writing of $1.00.

Newman Ferrara LLP Announces Corporate Governance Investigation Of NewLink Genetics Corporation

Newman Ferrara LLP Announces Corporate Governance Investigation Of NewLink Genetics Corporation

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of NewLink Genetics Corporation ("NewLink" or the "Company") (NASDAQ:NLNK) into potential breaches of fiduciary duty...

NewLink Genetics Outlines 2018 Business Priorities To Support Phase 3 Pivotal Trial Of Indoximod Plus PD-1 Inhibitors

NewLink Genetics Outlines 2018 Business Priorities To Support Phase 3 Pivotal Trial Of Indoximod Plus PD-1 Inhibitors

NewLink Genetics updates financial and clinical guidance

Notable Thursday Option Activity: NLNK, SMG, LAD

Notable Thursday Option Activity: NLNK, SMG, LAD

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in NewLink Genetics Corp , where a total volume of 8,561 contracts has been traded thus far today, a contract volume which is representative of approximately 856,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 117.7% of NLNK's average daily trading volume over the past month, of 727,295 shares.

Relative Strength Alert For NewLink Genetics

Relative Strength Alert For NewLink Genetics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

NewLink Genetics Reports Third Quarter 2017 Financial Results And Updates Indoximod Program

NewLink Genetics Reports Third Quarter 2017 Financial Results And Updates Indoximod Program

- Management to Host Conference Call Today at 8:30 a.m. ET

NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers

NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers

The U.S. Food and Drug Administration has granted orphan drug designation to NewLink's indoximod, a potential treatment for patients with Stage IIb-IV melanoma.

Interesting NLNK Put And Call Options For November 17th

Interesting NLNK Put And Call Options For November 17th

Investors in NewLink Genetics Corp saw new options begin trading this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NLNK options chain for the new November 17th contracts and identified one put and one call contract of particular interest.

TheStreet Quant Rating: D (Sell)